Ongoing trials

All Multiple Myeloma patients including smoldering Multiple Myeloma

A phase 1/2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed KRAS or NRAS codon 12/13 mutation and high risk smoldering multiple myeloma, or multiple myeloma, and evidence of measurable disease following ≥ 1 line of treatment

Smoldering Multiple Myeloma:

Hovon147: A randomized phase II study comparing Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in high- risk smoldering Multiple Myeloma

Newly Diagnosed Multiple Myeloma

REMNANT: The Relapse from MRD negativity as indication for treatment (REMNANT) study- A randomized, open label two-part (phase II and III) to assess whether earlier treatment of relapse, based on Measurable Residual Disease (MRD) prolongs progression free and overall survival and improves quality of life for myeloma patients

COBRA: A randomized, open-label phase 3 study of Carfilzomib, Lenalidomide, and Dexamethasone versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients with newly Diagnosed multiple myeloma

CARTITUDE5: Phase 3 randomized study comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a chimeric antigen receptor T cell (CAR-T) therapy directed against BCMA, versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) therapy in participants ineligible for hematopoietic stem cell transplant 

MagnetisMM-7: A phase 3 randomised Study comparing Elranatamab with Lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma patients 

SABLe: A phase 2 study evaluating Selinexor with alternating Bortezomib or Lenalidomide plus Dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients

Relapsed/Refractory Multiple Myeloma

MagnetisMM-5: A phase3 randomised study of Elranatamab monotherapy versus Elranatamab + Daratumumab versus Daratumumab + Pomalidomide + Dexamethasone in participants with relapsed/refractory multiple myeloma

SUCCESSOR-2: A randomized phase 3 study to evaluate mezigdomide in combination with Carfilzomib and Dexamethasone (MEZiKd) versus Carfilzomib and Dexamethasone (Kd) in participants with relapsed or refractory multiple myeloma

IRAKLIA: A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of Isatuximab in combination with Pomalidomide and Dexamethasone in adult patients with relapsed and/or refractory multiple myeloma

EXCALIBER: A phase 3, randomized, open-label study comparing Iberdomide, Daratumumab and Dexamethasone (IBERDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in subjects with relapsed or refractory multiple myeloma 

DREAMM 5: A phase 1/2, randomized, open-label platform study utilizing a master protocol to study Belantamab Mafodotin as monotherapy and in combination with anti-cancer treatments in participants with relapsed/refractory multiple myeloma 

ACT: Phase 1/2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma

003: Phase 1b/2a study to evaluate mezigdomide in combination with other treatments in relapsed or refractory multiple myeloma

TED: An open-label phase 1, first-in-human, single agent, dose escalation study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR442257 in patients with relapsed and refractory multiple myeloma 

GO43073: A phase 1 study to evaluate the safety and pharmacokinetics of XMAB24306 in combination with Daratumumab in participants with relapsed/refractory multiple myeloma

GO43980: Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in combination with Cevostamab in Participants with relapsed/refractory multiple myeloma


BLENREP Effectiveness and Safety in Multiple Myeloma (BEaMM) – Real-world evidence on patients taking Belantamab Mafodotin in Europe

Upcoming trials:


Page visits: 10517